Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > January 20, 2020
Daily News
January 20, 2020
- Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise
January 20, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
- Impact of Oligonucleotides - 3: Advances in Modified Oligo Technologies Pave Way for Innovative Drug Arrivals
January 20, 2020
- Forxiga Filed for Chronic Heart Failure in Japan: AstraZeneca
January 20, 2020
- Nichi-Iko Quits Herceptin Biosimilar, Focus Now on Avastin Follow-On
January 20, 2020
- Mitsubishi Tanabe to Be Delisted from TSE on February 27
January 20, 2020
- Astellas to Build New API Facility for Prograf in Toyama
January 20, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…